$-0.31 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED)

February 15, 2018 - By Vivian Park

 $ 0.31 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED)
Investors sentiment increased to 0.71 in Q3 2017. Its up 0.12, from 0.59 in 2017Q2. It improved, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported.
Vanguard Gp invested in 1.03M shares or 0% of the stock. Glenmede Na reported 3,600 shares. Manufacturers Life Ins The owns 2,762 shares or 0% of their US portfolio. Element Cap Management Ltd Liability holds 25,249 shares or 0.05% of its portfolio. Blackrock has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Moreover, Schwab Charles Management Incorporated has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Plante Moran Financial Advsr Ltd Liability Corporation has invested 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Fny Managed Accounts Limited Liability Corporation holds 3,200 shares. Citigroup Incorporated invested in 0% or 1,704 shares. Comml Bank Of Montreal Can holds 0% or 8,000 shares in its portfolio. Geode Capital Mgmt owns 124,569 shares. Moreover, Citadel Limited has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 33,587 shares. Jacobs Levy Equity Mngmt Inc accumulated 41,800 shares. State Street Corp has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 13,100 shares. 219,420 were accumulated by First Eagle Investment Ltd Liability.

Since October 10, 2017, it had 0 insider buys, and 5 selling transactions for $27,111 activity. Hager Alicia J. had sold 1,248 shares worth $5,295. HASTINGS PAUL J sold $5,931 worth of stock or 1,398 shares. 1,248 shares valued at $5,295 were sold by Gurney Austin on Tuesday, October 10. On Tuesday, October 10 the insider Lewicki John A. sold $5,295.

Analysts expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report $-0.31 EPS on March, 14.They anticipate $0.39 EPS change or 55.71 % from last quarter’s $-0.7 EPS. After having $-0.28 EPS previously, OncoMed Pharmaceuticals, Inc.’s analysts see 10.71 % EPS growth. The stock decreased 1.45% or $0.03 during the last trading session, reaching $2.04. About 57,814 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since February 15, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Ratings Coverage

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The rating was initiated by Jefferies on Wednesday, September 9 with “Buy”. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. As per Tuesday, December 20, the company rating was initiated by SunTrust. SunTrust maintained it with “Hold” rating and $4.0 target in Friday, October 6 report. The rating was downgraded by BMO Capital Markets on Tuesday, April 11 to “Market Perform”. The company was maintained on Wednesday, March 9 by JMP Securities. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Mkt Perform” rating given on Monday, January 25 by Leerink Swann. The rating was maintained by Mizuho with “Neutral” on Wednesday, January 6. Jefferies maintained it with “Buy” rating and $5.0 target in Thursday, August 24 report. The company was initiated on Tuesday, April 12 by BMO Capital Markets.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $77.23 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Seekingalpha.com which released: “Is OncoMed A Contrarian Buy?” on May 25, 2017, also Businesswire.com with their article: “Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed …” published on January 08, 2018, Globenewswire.com published: “OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence” on September 19, 2017. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Fool.com and their article: “Why Oncomed Pharmaceuticals Inc. Got Slaughtered Today” published on April 10, 2017 as well as Globenewswire.com‘s news article titled: “OncoMed Announces Chairman, President and Chief Executive Officer Paul J …” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.